NCTN Leukemia Trials Portfolio (Open as of 10/15/2019)
Each far right box includes the NCTN protocol number with a hyperlink to the associated ClinicalTrials.gov webpage. Click on it to view the protocol title and study information.

**Acute lymphoblastic leukemia (ALL)**
- Newly diagnosed, CD22-positive, Ph negative
  - Age ≥ 18 years and < 40 years
  - Protocol: A041501
- Ph negative: Newly diagnosed; Ph positive or Ph-like: Newly diagnosed or relapsed/refractory
  - Age ≥ 65 years
  - Protocol: S1318
- Relapsed or refractory
  - Age ≥ 18 years
  - Protocol: EA9152
- Newly diagnosed AML or Myelodysplastic syndrome with excess blasts-2 (MDS-EB-2)
  - Age ≥ 60 years
  - Protocol: S1612
- Newly diagnosed, no activating FLT3 mutation
  - Age ≥ 60 years
  - Protocol: A041701
- Newly diagnosed, Ph negative
  - Age ≥ 30 years and ≤ 70 years
  - Protocol: E1910
- Ph negative, CD22-positive
  - Age ≥ 60 years, Newly diagnosed
  - Protocol: A041703
  - Age ≥ 18 years, Relapsed or refractory
- **Acute myeloid leukemia (AML)**
  - Newly diagnosed AML or Myelodysplastic syndrome with excess blasts-2 (MDS-EB-2)
  - Age ≥ 60 years
  - Protocol: S1612
- Newly diagnosed, no activating FLT3 mutation
  - Age ≥ 60 years
  - Protocol: A041701
- **Precursor B-lymphoblastic leukemia (B-precursor ALL)**
  - Newly diagnosed, Ph negative
  - Age ≥ 30 years and ≤ 70 years
  - Protocol: E1910
  - Ph negative, CD22-positive
  - Age ≥ 60 years, Newly diagnosed
  - Protocol: A041703
  - Age ≥ 18 years, Relapsed or refractory
- **Chronic lymphocytic leukemia (CLL)**
  - Untreated disease, meet indication for treatment
    - Age ≥ 18 years and < 70 years
    - Protocol: EA9161
    - Age ≥ 70 years
    - Protocol: A041702
- **Chronic myelogenous leukemia (CML)**
  - Philadelphia chromosome positive
    - Age ≥ 18 years
    - Protocol: EA9171
  - Philadelphia chromosome positive
    - Age ≥ 18 years
    - Protocol: S1712
    - Age ≥ 70 years
    - Protocol: EA9171
<table>
<thead>
<tr>
<th>Protocol Number</th>
<th>Phase</th>
<th>Protocol Title</th>
</tr>
</thead>
<tbody>
<tr>
<td>A041501</td>
<td>III</td>
<td>A Phase III Trial to Evaluate the Efficacy of the Addition of Inotuzumab Ozogamicin (a Conjugated Anti-CD22 Monoclonal Antibody) to Frontline Therapy in Young Adults (Ages 18-39 Years) with Newly Diagnosed Precursor B-Cell ALL</td>
</tr>
<tr>
<td>A041701</td>
<td>II/III</td>
<td>A Randomized Phase II/III Study of Conventional Chemotherapy +/- Uproleselan (GMI-1271) in Older Adults with Acute Myeloid Leukemia Receiving Intensive Induction Chemotherapy</td>
</tr>
<tr>
<td>A041702</td>
<td>III</td>
<td>A Randomized Phase III Study of Ibrutinib Plus Obinutuzumab Versus Ibrutinib Plus Venetoclax and Obinutuzumab in Untreated Older Patients (&gt;70 Years of Age) with Chronic Lymphocytic Leukemia (CLL)</td>
</tr>
<tr>
<td>A041703</td>
<td>II</td>
<td>A Phase II Study of Inotuzumab Ozogamicin Followed by Blinatumomab for Ph-Negative, CD22-Positive B-Lineage Acute Lymphoblastic Leukemia in Newly Diagnosed Older Adults or Adults with Relapsed or Refractory Disease</td>
</tr>
<tr>
<td>E1910</td>
<td>III</td>
<td>A Phase III Randomized Trial of Blinatumomab for Newly Diagnosed BCR-ABL-Negative B Lineage Acute Lymphoblastic Leukemia in Adults</td>
</tr>
<tr>
<td>EA9152</td>
<td>I/II</td>
<td>A Phase IB/II Study of Venetoclax (ABT-199) in Combination with Liposomal Vincristine in Patients with Relapsed or Refractory T-Cell or B-Cell Acute Lymphoblastic Leukemia</td>
</tr>
<tr>
<td>EA9161</td>
<td>III</td>
<td>A Randomized Phase III Study of the Addition of Venetoclax to Ibrutinib and Obinutuzumab Versus Ibrutinib and Obinutuzumab in Untreated Younger Patients with Chronic Lymphocytic Leukemia (CLL)</td>
</tr>
<tr>
<td>EA9171</td>
<td>II</td>
<td>Phase II Study of Adding the Anti-PD-1 Pembrolizumab to Tyrosine Kinase Inhibitors in Patients with Chronic Myeloid Leukemia and Persistently Detectable Minimal Residual Disease</td>
</tr>
<tr>
<td>S1318</td>
<td>II</td>
<td>A Phase II Study of Blinatumomab (NSC-765986) and POMP (Prednisone, Vincristine, Methotrexate, 6-Mercaptopurine) for Patients &gt;/= 65 Years of Age with Newly Diagnosed Philadelphia-Chromosome Negative (Ph-) Acute Lymphoblastic Leukemia (ALL) and of Dasatinib (NSC-732517), Prednisone and Blinatumomab for Patients &gt;/= 65 Years of Age with Newly Diagnosed Philadelphia-Chromosome Positive (Ph+) ALL, Relapsed/Refractory Philadelphia-Chromosome Positive (Ph+) ALL, and Philadelphia-Chromosome-Like Signature (Ph-Like) ALL (Newly Diagnosed or Relapsed/Refractory) with Known or Presumed Activating Dasatinib-Sensitive Mutations or Kinase Fusions (DSMKF)</td>
</tr>
<tr>
<td>S1612</td>
<td>II/III</td>
<td>A Randomized Phase II/III Trial of “Novel Therapeutics” Versus Azacitidine in Newly Diagnosed Patients with Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS), Age 60 or Older (LEAP: Less-Intense AML Platform Trial)</td>
</tr>
<tr>
<td>S1712</td>
<td>II</td>
<td>A Randomized Phase II Study of Ruxolitinib (NSC-752295) in Combination with BCR-ABL Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia (CML) Patients with Molecular Evidence of Disease</td>
</tr>
</tbody>
</table>